Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01527591
NA

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

Sponsor: University of California, Los Angeles

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.

Official title: Safety And Long-Term Immunogenicity Of The 13-Valent Pneumococcal Conjugate Vaccine In Children Who Are Solid Organ Transplant Recipients

Key Details

Gender

All

Age Range

12 Months - 59 Months

Study Type

INTERVENTIONAL

Enrollment

17

Start Date

2012-02-01

Completion Date

2025-12-30

Last Updated

2025-04-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

Pneumococcal Conjugate Vaccine 13 (PCV13)

A single intramuscular dose of 0.5 mL.

Locations (1)

UCLA

Los Angeles, California, United States